Leukemia corrects author name in CLL t(14;19) study record
A correction has been published for the chronic lymphocytic leukemia study on patients harboring t(14;19), an ERIC collaborative analysis that appeared in _Leukemia_. The amendment is narrow but important: the author’s name was originally written incorrectly and has now been corrected in the journal record.
In a literature field where multi-institutional genomics papers depend on precise attribution, even a seemingly small spelling error can matter. Authorship is not a cosmetic detail. It is the permanent link between a researcher, a dataset, a disease subtype, and the clinical interpretation that later investigators may rely on when comparing cohorts or designing follow-up studies.
Why a corrected author line matters in rare CLL biology
The original article focused on CLL with t(14;19), a cytogenetically distinct subgroup that has drawn attention because rare genomic abnormalities often carry disproportionate biologic and prognostic significance. Studies of this kind usually depend on tight coordination across centers, with each contributor handling a different piece of the diagnostic and transcriptomic puzzle. In that setting, author identity is part of the scientific chain of custody.
A correction to the byline does not alter the biology under review, but it does affect the fidelity of the publication trail. For hematologic oncology, where genomic subclassification increasingly shapes how clinicians interpret disease behavior, the accuracy of the scholarly record remains part of quality control. Misattribution can complicate indexing, citation tracking, and the visibility of investigators whose work is tied to a rare molecular entity.
The corrected paper remains anchored to the same original publication, which first appeared on 19 September 2025 and was later amended on 16 October 2026. The formal correction preserves continuity between the original report and the journal’s updated metadata, allowing readers and databases to align the article with the correct author information.
The clinical value of precision extends beyond the laboratory
For patients with leukemia, genomics is not an abstract exercise. A rare rearrangement such as t(14;19) often prompts deeper scrutiny of disease tempo, clonal architecture, and the biologic pathways that may distinguish one patient subgroup from another. That kind of work is only as reliable as the record attached to it. When an author name is wrong, the paper’s content may remain intact, but the scholarly map used to trace responsibility, expertise, and prior contributions becomes less accurate.
The correction also reflects an increasingly visible reality in modern hematology: large cooperative studies are built by dispersed teams, and those teams depend on editorial precision to keep the scientific archive usable. A single CLL variant can move through pathology, sequencing, translational interpretation, and clinical framing across many sites. The publication trail has to carry that work cleanly.
What the amendment does and does not change
This correction addresses the author name only. It does not introduce new data, revise the disease characterization, or change the conclusions of the original article. No new patient cohort, endpoint, or analytic result was added in the correction notice. The scope is administrative and bibliographic, not scientific.
Still, these notices are part of responsible publishing. Genomic oncology papers live long lives: they are cited in reviews, pulled into meta-analyses, and used by readers searching for signal in rare subtypes. If a name is incorrect, the paper can become harder to connect to a researcher’s body of work, and that has downstream consequences for academic credit and discoverability.
The correction also serves as a reminder that precision in oncology is not limited to sequencing panels and fluorescence signals. It extends to the paper trail itself. In a field where small genetic lesions may define a biologic subgroup, the bibliographic record should be just as exact.
The corrected record in the context of ERIC collaboration
ERIC collaborations typically bring together multiple investigators across centers and countries to study uncommon patterns in chronic lymphocytic leukemia. Such studies are often valuable precisely because they collect enough cases to examine rare lesions that individual centers might see only sporadically. When that work appears in print, the authorship list becomes a durable marker of who contributed to the cohort assembly, interpretation, and translational framing.
The corrected citation now aligns the article with its intended authorship. For readers who follow rare CLL genomics, the updated record matters for citation accuracy, literature searches, and institutional attribution. For the journal archive, it keeps the paper consistent with the author information intended by the collaboration.
No new therapeutic implication emerges from the correction itself. The clinical relevance remains tied to the original study of CLL with t(14;19), while the present notice simply repairs the publication record. For a rare-leukemia paper that may be revisited repeatedly by clinicians, laboratorians, and genomic researchers, that repair is the whole point.